Humalog Mix50 Insulin Lispro Protamine and Insulin Lispro Injection (50R)

1. Indications and Usage
Diabetes Mellitus: Treatment of adult and pediatric patients with diabetes mellitus who require insulin for the regulation of hyperglycemia.
2. Dosage and Administration
Dosage: Individualized based on blood glucose monitoring and clinical response.
Administration: Subcutaneous injection only. Never for intravenous infusion or insulin pump therapy.
Timing: Administer immediately before a meal or shortly after.
Injection Sites: Abdomen, thigh, buttocks, or upper arm. Rotate sites to prevent lipodystrophy.
Reconstitution: Gently roll or invert the pen between hands before each injection to ensure a uniform suspension.
3. Mechanism of Action
Dual-Action: Combines rapid-acting soluble lispro (50%) for immediate postprandial control and protamine-crystallized lispro (50%) for delayed absorption and basal coverage.
Pharmacokinetics: Onset within 15 minutes; biphasic peak effect; duration of action up to 24 hours.
4. Safety and Warnings
Hypoglycemia: The most common adverse reaction. Risk increases with missed meals, excessive exercise, or dose mismatch.
Hypersensitivity: Severe allergic reactions (anaphylaxis) may occur.
Hypokalemia: Insulin therapy may cause a shift of potassium into cells.
Transitions: Dose adjustments are necessary when switching between different insulin types or brands.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Hypoglycemia, injection site reactions, lipodystrophy, and weight gain.
Clinical Research: Clinical trials demonstrate efficacy in controlling both fasting and postprandial hyperglycemia.
6. Drug Interactions
Agents Increasing Glucose: Corticosteroids, oral contraceptives, thyroid hormones, and sympathomimetics may increase insulin requirements.
Agents Decreasing Glucose: Oral antidiabetic drugs, ACE inhibitors, salicylates, and alcohol may potentiate hypoglycemic effects.
Beta-Blockers: May mask clinical signs of hypoglycemia (e.g., tachycardia and tremors).
7. Pharmaceutical Information
Active Ingredient: Recombinant human insulin analogue (Lispro).
Excipients: Metacresol, glycerin, dibasic sodium phosphate, zinc oxide, protamine, and water for injection.
Appearance: White, cloudy suspension.
Storage: Unopened pens should be refrigerated (2°C to 8°C). In-use pens may be kept at room temperature (below 30°C) for up to 28 days.